FIELD: medicine.
SUBSTANCE: invention refers to treating stroke, particularly to a new method for treating stroke involving administration of Imatinib. Imatinib is administered to a patient in dose of 650 to 1600 mg/day on day 1 and in dose of 650 to 1200 mg/day for at least 2 successive consecutive days, preferably for at least 3 successive consecutive days and most preferably for at least 4 successive consecutive days. Imatinib administration for more than 3 days improves the neurological outcome in the post-stroke patients, as well as improves functional independence of the patient.
EFFECT: invention improves the treatment of acute ischemic or haemorrhagic stroke, widens the therapeutic window for thrombolysis.
10 cl, 4 dwg, 3 tbl
